Louise Chen
Stock Analyst at Scotiabank
(4.41)
# 358
Out of 5,131 analysts
295
Total ratings
48.07%
Success rate
21.97%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $53 → $60 | $55.86 | +7.41% | 2 | Jan 9, 2026 | |
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $32.01 | +9.34% | 4 | Dec 5, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $110.53 | +8.57% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $796.55 | -3.33% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $23.83 | +235.71% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.64 | +240.91% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $24.90 | -43.78% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $2.31 | +419.48% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.58 | +180.90% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $77.53 | -29.06% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.84 | +428.17% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $92.41 | -45.89% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $7.74 | +93.80% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $35.35 | -51.91% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $72.37 | -3.27% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $17.77 | +181.37% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $13.06 | +129.71% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $18.55 | +196.50% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.55 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $58.81 | +172.06% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $46.05 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $220.08 | +9.05% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.48 | +76.61% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $204.39 | +5.19% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.49 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.98 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,063.56 | -16.79% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.65 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.03 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.96 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.77 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.65 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.60 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.82 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.07 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.67 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.73 | +1,642.63% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.15 | +132.56% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.72 | +239.67% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $28.22 | +77.18% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $2.16 | +131.48% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.57 | +1,479.78% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.05 | +160,714,185.71% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $294.45 | -12.38% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.39 | +3,497.12% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.36 | +1,370.59% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.27 | +518.98% | 1 | Jun 22, 2017 |
Bristol-Myers Squibb Company
Jan 9, 2026
Maintains: Sector Perform
Price Target: $53 → $60
Current: $55.86
Upside: +7.41%
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $32.01
Upside: +9.34%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $110.53
Upside: +8.57%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $796.55
Upside: -3.33%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $23.83
Upside: +235.71%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.64
Upside: +240.91%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $24.90
Upside: -43.78%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $2.31
Upside: +419.48%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.58
Upside: +180.90%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $77.53
Upside: -29.06%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.84
Upside: +428.17%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $92.41
Upside: -45.89%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $7.74
Upside: +93.80%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $35.35
Upside: -51.91%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $72.37
Upside: -3.27%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $17.77
Upside: +181.37%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $13.06
Upside: +129.71%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $18.55
Upside: +196.50%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.55
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $58.81
Upside: +172.06%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $46.05
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $220.08
Upside: +9.05%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.48
Upside: +76.61%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $204.39
Upside: +5.19%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.49
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.98
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,063.56
Upside: -16.79%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.65
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.03
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.96
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.77
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.65
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.60
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.82
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.07
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.67
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.73
Upside: +1,642.63%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.15
Upside: +132.56%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.72
Upside: +239.67%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $28.22
Upside: +77.18%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $2.16
Upside: +131.48%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.57
Upside: +1,479.78%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.05
Upside: +160,714,185.71%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $294.45
Upside: -12.38%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.39
Upside: +3,497.12%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.36
Upside: +1,370.59%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.27
Upside: +518.98%